Important industry conferences and events (such as the recent ENA 2020 symposium where cancer researchers shared new data on drug candidates from various biotech companies), upcoming data releases and big upticks in insider buying make the five biotech penny stocks highlighted in today’s article ones to watch this week and in the weeks ahead. For these five biotech penny stocks…
The coronavirus pandemic is surging. The economy is in a precarious state. The outcome of the presidential election may well be contested. International tensions are rising. And the author of today’s article advises that “These risks are presenting a once-in-a-lifetime chance to turbocharge your investment gains.” How? By trading options, which he argues is easier than many investors think. For…
Investors looking for profitable pandemic plays have a plethora of biotech firms to choose from. The one that’s the subject of today’s article, however, may not be one of them, despite the fact that some are betting on it as a COVID play. In fact, one market analyst has warned “Investors beware” in regards to this stock. For the stock…
How important a factor is the outcome of the presidential election for the direction of stocks? Not as important as a COVID-19 vaccine, according to Goldman Sachs. With this in mind, today’s article highlights two therapeutics companies focused on battling neurodegenerative diseases where analysts at Goldman see significant upside potential. For these two stocks – both of which have earned…
“Biopharma stocks are risky bets that could fetch disproportionate gains or wipe away one’s entire investment thanks to their vulnerability to catalytic events,” acknowledges the author of today’s article before proceeding to identify nine biotech stocks with key catalysts in the final months of 2020. For these nine stocks and their respective fourth-quarter catalysts and price targets, CLICK HERE.
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering…
“The premise here is simple: biotech investing is just as it was before COVID-19 and as it will be when the pandemic is finally over,” begins the author of today’s article. If one accepts this premise, what does that mean for investing in the three fronts of the war on the coronavirus (testing, treatment and vaccination)? For the author’s overview…
Dr. David Nierengarten, Managing Director and Head of Healthcare Equity Research at Wedbush Securities, sees potential in many biotech stocks, especially in the genetic-medicine and oncology spaces. For several specific genetic-medicine and oncology names that Nierengarten is particularly bullish on – including one company with a gene therapy for a rare retinal disease that causes significant vision loss (and sometimes…
A clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics and a clinical- stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease are among seven new biotech stocks to watch highlighted in today’s article, which also highlights new stocks to watch in the tech, defense, and real estate sectors. For these…
The biotech firm highlighted in today’s article, which in the past year has refocused its efforts on a newer cancer-fighting technology, is the No. 4 best-performing stock on the Nasdaq Composite Index and the No. 1 best-performing stock on Canada’s S&P/TSX Composite Index – and despite having already experienced a 3,600% surge, the author notes that “every analyst covering the…